Abstract:Abstract Background: Benzene and ethylene oxide are considered carcinogenic to humans by International Agency for Research on Cancer based on experimental animal studies whereas acrolein and crotonaldehyde are considered weak carcinogens. They are present in cigarette smoke and other environmental sources. Epidemiological data linking them to lung cancer in humans have been lacking. Methods: A nested case-control study of lung cancer was conducted within the Shanghai Cohort Study, a population-based prospective cohort of 18,244 Chinese men aged 45–64 years at enrollment during 1986–1989. In addition to in-person interviews for information on use of tobacco and alcohol, usual diet, and medical history, each participant provided a 10-ml blood sample and one single void urine sample at baseline. Annual follow-ups to each surviving subject were conducted to identify incident cancer cases and death. The present study included 96 cases who never smoked and 343 cases who smoked cigarettes at baseline. One control for each case was randomly chosen among cohort participants. The control was matched to the index case by age (±2 years), date of urine collection (±1 month), neighborhood of residence, and smoking status. We quantified urinary mercapturic acid metabolites for benzene [S-phenyl mercapturic acid (SPMA)], ethylene oxide [2-hydroxyethyl mercapturic acid (HEMA)], acrolein [3-hydroxypropyl mercapturic acid (HPMA)], and crotonaldehyde [4-hydroxybut-2-yl mercapturic acid (HBMA)] for all study subjects. For current smokers, we also determined urinary levels of cotinine and its glucuronides (total cotinine), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL), and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and its glucuronides (PheT), validated biomarkers of uptake and metabolism of nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and polycyclic aromatic hydrocarbons (PAH), respectively, for current smokers. The odds ratio (OR) and 95% confidence interval (CI) for lung cancer with urinary biomarkers were estimated using an unconditional logistic regression method. Results: Among current smokers, all measured mercapturic acid metabolites were statistically significantly higher in cases than controls. Compared with the lowest quartile, ORs (95% CIs) of lung cancer for highest quartile were 1.80 (1.14–2.85) for SPMA, 2.13 (1.34–3.37) for HEMA, 2.00 (1.25–3.20) for HPMA, and 1.95 (1.22–3.12) for HBMA (all P's for trend <0.01). Further adjustment for urinary total cotinine, total NNAL, and PheT significantly attenuated and resulted in a null association between all mercapturic acid metabolites and lung cancer risk (all P's for trend >0.50). Among never smokers, cases showed elevated levels of SPMA, but similar levels of HEMA, HPMA, and HBMA, compared with controls. OR for lung cancer was 2.11 (95% CI 1.05–4.23) for highest tertile of SPMA (P for trend = 0.026). There was no statistically significant association between urinary HEMA, HPMA or HBMA and lung cancer risk among never smokers. Conclusion: Urinary SPMA, a mercapturic acid metabolite for benzene, is statistically significant associated with lung cancer risk among never smokers whereas this positive association among current smokers could be largely explained by urinary biomarkers for nicotine, NNK and PAH, established risk factors for lung cancer for smokers in the present study population. Mercapturic acid metabolites for acrolein, crotonaldehyde, and ethylene oxide are not independent predictors for lung cancer for both smokers and nonsmokers. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A6.

Abstract LB136: Global metabolomics identified promising biomarkers for lung cancer risk among former smokers

Abstract 4974: Prospective study of untargeted urinary metabolomics and risk of lung cancer among female never-smokers in Shanghai, China

A nested case‐control study of untargeted plasma metabolomics and lung cancer among never‐smoking women within the prospective Shanghai Women's Health Study

Abstract 3427: Serum metabolites and pancreatic ductal adenocarcinoma in two prospective cohorts

Abstract 3483: Epigenome-wide association study of lung cancer among never-smokers in two prospective cohorts in Shanghai

Association of Untargeted Urinary Metabolomics and Lung Cancer Risk among Never-Smoking Women in China

Prediagnostic plasma metabolite concentrations and liver cancer risk: a population-based study of Chinese men

Metabolomics Profiles of Smokers from Two Ethnic Groups with Differing Lung Cancer Risk

Circulating Markers of Cellular Immune Activation in Prediagnostic Blood Sample and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3).

P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling

Abstract 784: Proteome-wide mendelian randomization identifies causal association between plasma proteins and lung cancer

Metabolomics-based search for lung cancer markers among patients with different smoking status

High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis

Abstract A6: Urinary Levels of Volatile Organic Carcinogens and Toxicant Biomarkers in Relation to Lung Cancer Development in Both Smokers and Nonsmokers: the Shanghai Cohort Study

Abstract LB-298: the Use of Lung Cancer Risk Prediction Model to Stratify Heavy Smokers: the Power of Routinely Collected Lab Data

Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study

Abstract 3432: Blood metabolomic profile of glioma risk: A pooled, multi-cohort analysis in COMETS

A Prospective Investigation of Circulating Metabolome Identifies Potential Biomarkers for Gastric Cancer Risk

Identification of Plasma Metabolites Associated with Lung Cancer Survival

TheAbility of Bilirubin in Identifying Smokerswith Higher Risk of Lung Cancer : A Large Cohort Study in Conjunction with Global Metabolomic Pro Fi Ling

Exploratory investigation of plasma metabolomics in human lung adenocarcinoma.